Amylyx reports avexitide cuts severe hypoglycemia by 55% in bariatric surgery patients

Amylyx Pharmaceuticals announced that its GLP-1 blocker avexitide achieved the primary endpoint in a late‑stage trial, reducing serious to severe hypoglycemic events by 55% compared with placebo in patients who had recently undergone bariatric surgery.

The study also reported a favorable safety profile, with most adverse events classified as mild or moderate. The most common side effects were diarrhea and injection‑site bruising or redness.

Based on these results, Amylyx plans to submit a formal request to the U.S. Food and Drug Administration for approval of avexitide before the end of the year.